279 related articles for article (PubMed ID: 9400943)
1. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
2. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
Veal GJ; Dias C; Price L; Parry A; Errington J; Hale J; Pearson AD; Boddy AV; Newell DR; Tilby MJ
Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793
[TBL] [Abstract][Full Text] [Related]
3. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.
Ghazal-Aswad S; Tilby MJ; Lind M; Baily N; Sinha DP; Calvert AH; Newell DR
Ann Oncol; 1999 Mar; 10(3):329-34. PubMed ID: 10355578
[TBL] [Abstract][Full Text] [Related]
5. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
6. Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
Ma J; Verweij J; Planting AS; de Boer-Dennert M; van Ingen HE; van der Burg ME; Stoter G; Schellens JH
Br J Cancer; 1995 Mar; 71(3):512-7. PubMed ID: 7880732
[TBL] [Abstract][Full Text] [Related]
7. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
Schellens JH; Ma J; Planting AS; van der Burg ME; van Meerten E; de Boer-Dennert M; Schmitz PI; Stoter G; Verweij J
Br J Cancer; 1996 Jun; 73(12):1569-75. PubMed ID: 8664132
[TBL] [Abstract][Full Text] [Related]
8. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
Motzer RJ; Reed E; Perera F; Tang D; Shamkhani H; Poirier MC; Tsai WY; Parker RJ; Bosl GJ
Cancer; 1994 Jun; 73(11):2843-52. PubMed ID: 7514956
[TBL] [Abstract][Full Text] [Related]
9. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
[TBL] [Abstract][Full Text] [Related]
11. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.
Parker RJ; Gill I; Tarone R; Vionnet JA; Grunberg S; Muggia FM; Reed E
Carcinogenesis; 1991 Jul; 12(7):1253-8. PubMed ID: 2070490
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
van Moorsel CJ; Kroep JR; Pinedo HM; Veerman G; Voorn DA; Postmus PE; Vermorken JB; van Groeningen CJ; van der Vijgh WJ; Peters GJ
Ann Oncol; 1999 Apr; 10(4):441-8. PubMed ID: 10370787
[TBL] [Abstract][Full Text] [Related]
14. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
[TBL] [Abstract][Full Text] [Related]
15. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.
Korst AE; van der Sterre ML; Gall HE; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
Clin Cancer Res; 1998 Feb; 4(2):331-6. PubMed ID: 9516919
[TBL] [Abstract][Full Text] [Related]
16. Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues.
Jarvis IW; Meczes EL; Thomas HD; Edmondson RJ; Veal GJ; Boddy AV; Ottley CJ; Pearson DG; Tilby MJ
Biochem Pharmacol; 2012 Jan; 83(1):69-77. PubMed ID: 22015635
[TBL] [Abstract][Full Text] [Related]
17. Formation of platinum-DNA adducts in pediatric patients receiving carboplatin.
Tonda ME; Murry DJ; Rodman JH
Pharmacotherapy; 1996; 16(4):631-7. PubMed ID: 8840369
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
19. The formation and persistence of carboplatin-DNA adducts in rats.
Blommaert FA; Michael C; van Dijk-Knijnenburg HC; Schornagel JH; den Engelse L; Fichtinger-Schepman AM
Cancer Chemother Pharmacol; 1996; 38(3):273-80. PubMed ID: 8646803
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies.
Perez RP; Chen E; Thaddeus Beck J; Shirai K; Neil Hayes D; Shen T; Baldwin JR; Bryant KB; He S; Chin S
Pharmacol Res Perspect; 2019 Dec; 7(6):e00519. PubMed ID: 31788317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]